IP Generator, Inc., (“IPG”) and National Research and Development Institute, RIKEN (“RIKEN”), based in Saitama, Japan, have entered into a Drug Discovery Alliance Agreement (“this agreement”) dated June 3, 2022. This agreement, executed with the support of RIKEN Innovation Co., Ltd. (RIKEN Innovation), establishes a formal framework for the incorporation of promising drug target leads from RIKEN into IPG’s drug discovery platform. The program enables RIKEN to propose drug seeds to IPG for identification and development of lead compounds or modalities with the goal of licensing clinical development candidates to pharmaceutical companies. IPG aims for the efficient creation of innovative medicines and hopes to contribute to solving global social issues …
Continue reading “IP Generator, Inc. and RIKEN Announce Drug Discovery Alliance Agreement”